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Introduction
The HIV-1 Rev protein mediates the nuclear export of viral
mRNA, thus enabling formation of new infectious virus parti-
cles.[1, 2] The 13 kDa Rev protein consists of several motifs that
play important roles in its cellular function. The leucine-rich
motif (LRM, residues 75–83), located at the C terminus operates
as a nuclear export signal (NES). The arginine-rich motif (ARM,
residues 34–50) acts as the nuclear-localization signal (NLS)
and as a binding site for the Rev response element (RRE),
which is present in all incompletely spliced viral mRNAs.[3–6] Al-
though Rev was discovered nearly three decades ago,[7] bio-
chemical and structural studies aimed at understanding the
structural and functional aspects of the Rev protein are still
limited because of its strong tendency to oligomerize, aggre-
gate, and precipitate.[4, 8,9] As a result, the majority of the Rev
studies have been performed on peptides derived from the
protein sequence, and on Rev conjugates such as Rev-
GFP.[6,10–12] Only very recently was the X-ray structure of this
protein solved; however, it was complexed with a specifically
engineered monoclonal Fab (fragment antigen-binding) anti-
body that served as the solubilizing agent.[9] This structure re-
vealed that only the central part of the protein (residues 9–65)
is structured, while the rest is intrinsically disordered. Motivat-
ed by the important role of Rev in the HIV replication cycle,
and its potential as a drug target,[11,13,14] we developed two effi-
cient synthetic and recombinant methods that allow the pro-
duction of sufficient amounts of highly pure Rev, and provide
the flexibility to prepare novel synthetic analogues of Rev for
future studies to elucidate its structure–function relationship
with spatial and temporal control.
Total chemical synthesis of proteins offers exceptional op-
portunities for preparing unstable and novel proteins, in high
purity and large quantity, for functional and structural analy-
sis.[15,16] Moreover, the polypeptide is often assembled under
denaturing conditions, so the functional protein can be ach-
ieved by in vitro folding in the appropriate buffer when de-
sired. Native chemical ligation (NCL)[17] is a powerful method to
conjugate two unprotected peptides (by thiol-capture followed
The HIV-1 Rev protein is responsible for shuttling partially
spliced and unspliced viral mRNA out of the nucleus. This is a
crucial step in the HIV-1 lifecycle, thus making Rev an attractive
target for the design of anti-HIV drugs. Despite its importance,
there is a lack of structural, biophysical, and quantitative infor-
mation about Rev. This is mainly because of its tendency to
undergo self-assembly and aggregation; this makes it very dif-
ficult to express and handle. To address this knowledge gap,
we have developed two new highly efficient and reproducible
methods to prepare Rev in large quantities for biochemical
and structural studies: 1) Chemical synthesis by using native
chemical ligation coupled with desulfurization. Notably, we
have optimized our synthesis to allow for a one-pot approach
for the ligation and desulfurization steps; this reduced the
number of purification steps and enabled the obtaining of
desired protein in excellent yield. Several challenges emerged
during the design of this Rev synthesis, such as racemization,
reduced solubility, formylation during thioester synthesis, and
the necessity for using orthogonal protection during desulfuri-
zation; solutions to these problems were found. 2) A new
method for expression and purification by using a vector that
contained an HLT tag, followed by purification with a Ni
column, a cation exchange column, and gel filtration. Both
methods yielded highly pure and folded Rev. The CD spectra
of the synthetic and recombinant Rev proteins were identical,
and consistent with a predominantly helical structure. These
advances should facilitate future studies that aim at a better
understanding of the structure and function of the protein.
[a] P. Siman,+ T. Moyal, Prof. A. Brik
Department of Chemistry, Ben-Gurion University of the Negev
P.O. Box 653, Beer Sheva, 84105 (Israel)
Fax: (+972)8-6472943
E-mail : abrik@bgu.ac.il
[b] O. Blatt,+ Prof. A. Friedler
Institute of Chemistry, The Hebrew University of Jerusalem
Givat Ram, Jerusalem 91904 (Israel)
E-mail : assaf@chem.ch.huji.ac.il
[c] Dr. T. Danieli, Dr. M. Lebendiker
The Protein Expression and Protein Purification Facilities, Wolfson Centre
for Applied Structural Biology, The Hebrew University of Jerusalem
Safra Campus, Givat Ram, Jerusalem 91904 (Israel)
[d] Prof. H. A. Lashuel
Laboratory of Molecular Neurobiology and Neuroproteomics
Swiss Federal Institute of Technology Lausanne (EPFL)
FSV-BMI AI 2137.1 Station 15, 1015 Lausanne (Switzerland)
[+] These authors contributed equally to this work.
Supporting information for this article is available on the WWW under
http://dx.doi.org/10.1002/cbic.201100033.
ChemBioChem 0000, 00, 1 – 9  2011 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim &1&
These are not the final page numbers! 
by a spontaneous S–N acyl transfer) to form the polypeptide
chain in the native form. Chemical synthesis can be adopted
to prepare proteins of 70–200 residues,[18–20] thus making Rev a
suitable target for such an approach. On the other hand, when
attempting the chemical synthesis of full-length Rev by apply-
ing Cys-NCL, this strategy is challenged by the presence of two
native Cys residues at the C-terminus of Rev; these cannot
serve as ligation sites, and might require transient protection
during NCL synthesis of Rev. As a result, alternative NCL-based
strategies were considered for full-length Rev synthesis. One
such strategy is the use of ligation junctions that contain thiol-
modified residues that can be desulfurized later to give the
native structure. This NCL–desulfurization method, since its in-
vention for an Ala junction,[21] has captured the interest of sev-
eral laboratories, including ours, and enabled performing NCL
at Phe,[22] Val,[23,24] Leu,[25,26] Lys,[27,28] and Thr[29] ligation junc-
tions. Moreover, this concept has been extended to include
sugar-assisted ligation[30, 31] for glycopeptide synthesis, and
lysine-mediated peptide and protein ubiquitination.[27,32,33]
Results and Discussion
Chemical synthesis of HIV-1 Rev
In our synthesis strategy for obtaining Rev (Scheme 1) the pro-
tein sequence was divided into three fragments: residues 68–
116 (Rev1), 37–67 (Rev2) and 1–36 (Rev3). In this strategy, the
Ala residues at positions 37 and 68 were temporarily replaced
with Cys[21] to allow NCL between Rev1 and Rev2, and later
between Rev2–Rev1 and Rev3. After full assembly of the poly-
peptide sequence, a desulfurization step[34, 35] was employed to
convert Cys37 and Cys68 back to their native Ala forms. The
two native Cys residues at positions 85 and 89 were masked
temporarily with acetamidomethyl (Acm) protecting
groups,[36,37] to avoid conversion to Ala residues in the desul-
furization step; this was followed by selective Acm-deprotec-
tion to afford wild-type Rev protein.
The three peptide precursors, Rev1–3, were synthesized by
using Fmoc-SPPS. The Rev1 fragment (49-mer, bearing an N-
terminal Cys) was synthesized in 15% isolated yield. In the
cases of the Rev2 and Rev3 thioester fragments, the presence
of Ser and Gln, respectively, at the C-termini of the peptides
prompted us to prepare these peptide thioesters by applying
a side-chain anchoring strategy and Fmoc-SPPS.[38,39] Accord-
ingly, Rev2 was prepared in 25–30% isolated yield by anchor-
ing commercially available Fmoc(Ser)-OAll with boron trifluor-
ide etherate to trichloroacetimidate-activated Wang resin,[40,41]
followed by peptide elongation by Fmoc-SPPS (see the Sup-
porting Information). The Rev3 thioester was prepared in simi-
lar yield by anchoring Fmoc-(Glu)-OAll on Rink amide resin
(Supporting Information).[42–45]
We then turned our focus to the synthesis of the full length
Rev protein by applying the above-described strategy. We first
ligated Rev1 to Rev2 under NCL conditions, followed by con-
version of the 1,3-thiazolidine-4-carboxo (Thz) to Cys by using
methoxylamine,[46] to give Rev2–Rev1 in 35% isolated yield for
the two steps (Figure 1A and B). Subsequently, Rev2–Rev1
peptide was ligated to Rev3 to give the full length Rev poly-
peptide in 35% isolated yield (Figure 1C). We then applied
free radical desulfurization conditions[23,34,47] to yield the de-
sired desulfurized product (for native Ala residues) in 60% iso-
lated yield after 8 h (Supporting Information). The desulfurized
product was then subjected to Acm-removal conditions to
unmask the C-terminal Cys residues, and this furnished the de-
sired (native) Rev in 60% isolated yield. To determine whether
this synthetic Rev is able to adopt the native folded-state of
the protein, the polypeptide was solubilized in folding buffer
(Experimental Section), and its secondary structure was exam-
ined by circular dichroism (CD), and compared to that of the
recombinant Rev protein.[8] The CD spectrum of the synthetic
protein showed less-ordered secondary structure than that of
the recombinant protein.[8] Efforts to optimize the folding of
the synthetic proteins by changing buffer, temperature, and
concentration did not improve these results. We reasoned that
our synthesis strategy has some pitfalls, and required further
investigation and optimization.
We first suspected that one/both of the C-terminal residues
(Ser and Gln) of the thioester peptides had some racemization
that might have occurred during the thioester synthesis. How-
ever, several studies have reported the presence of just traces
Scheme 1. HIV-1 Rev sequence and NCL-based synthesis strategy (the liga-
tion junctions are highlighted within the sequence). Met1 was replaced with
Nle to avoid oxidation during synthesis and handling. a) NCL, b) Thz-Cys
conversion, c) desulfurization, d) Acm removal.
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of racemization at Gln thioesters[38,39,42–45, 48] when using proto-
cols similar to those used in our study (PyBOP-coupling condi-
tions) ; this rules out racemization at the Gln residue of Rev3.
On the other hand, the level of racemization in the case of the
C-terminal Ser thioester, which we prepared by using
BF3·etherate on trichloroacetimidate activated Wang resin, has
not been investigated.[40,41] Therefore, we sought to investigate
whether racemization had occurred at the C-terminal Ser
moiety of the Rev2 thioester, as this might interfere with the
folding of the protein. Indeed, careful investigation by HPLC
analysis revealed two peaks that eluted at different retention
times: these corresponded to Rev2 benzyl mercaptan/thioester
with a 7:3 ratio (Supporting Information).
Based on the above observations we modified our synthesis
strategy by including a racemization-free N-acyl urea
method[49] to give Rev2-Nbz in 30% isolated yield (Supporting
Information). Notably, after assembly of the Rev protein (with
Rev2-Nbz), the CD analysis revealed a spectrum that is consis-
tent with a predominantly helical protein, and that this was vir-
tually identical to that of the recombinant protein (Figure 2).
Western blot analysis of synthesized Rev showed that the pro-
tein is recognized by an anti-Rev antibody (Rat anti-Rev, Experi-
mental Section).
Notably, we were unable to prepare the Rev2-Nbz with
DCM as the solvent for the activation step with p-nitrophenyl-
chloroformate, despite efficient SPPS synthesis of this fragment
before this step (Supporting Information). We reasoned that
this peptide undergoes severe aggregation in DCM, and that
this renders the activation step very challenging. Thus we ex-
amined DMF, which is known to be a better solvent for long
peptides, as an alternative solvent. The activation step was suc-
cessfully achieved. However, we observed an additional 28 Da
in its mass; this presumably correlates with the incorporation
of a formyl group into this peptide. Peptide treatment with
methyl 3-mercaptopropionate led to elimination of the N-acyl-
urea moiety, to give a Rev2 thioester with the desired mass
(Supporting Information).
This also supports the hypothesis that the additional mass
was linked to the N-acylurea moiety rather than to the peptide.
We concluded that the formylation had occurred on the N-
acylurea moiety by a Vilsmeier–Haack reaction, due to the use
of p-nitrophenylchloroformate in DMF, thus generating the
active Vilsmeier reagent (Scheme 2).[50,51] Further analysis of the
formylation site on a short model-peptide (Leu-Leu-Nbz) re-
vealed that this modification had occurred on the free nitro-
gen of the imidazolinone moiety, as indicated by 1H and
13C NMR analysis (Supporting Information): the three aromatic
protons were intact after formylation, along with the presence
of a formyl proton at 8.5 ppm.
One-pot synthesis of HIV-1 Rev
The above-described strategy required four purification steps
to yield the final Rev protein in 6–7% total isolated yield. We
then tested a one-pot strategy for synthesis up to the Acm re-
moval step. This had two ligation reactions: Thz–Cys conver-
sion, and a desulfurization step. To allow desulfurization direct-
ly after the ligation, and Thz-Cys conversion, we first examined
the use of different thiol-additives as we realized that such a
thiol should aid several tasks. Firstly, it should activate the alkyl
thioester to permit an efficient NCL step; secondly, it reduces
Figure 1. Analytical HPLC monitoring of the synthesis of HIV-1 Rev protein
with NCL/orthogonal protection/desulfurization: A) Ligation between Rev1
(1.2 equiv) and Rev2 at 0 h. Peak a: Rev2 thioester, and peak b: Rev1 frag-
ment. B) Ligation between Rev1 and Rev2 after 18 h, followed by Thz to Cys
conversion after 10 h. Peak c: hydrolyzed Rev2 (obs. : 3996 Da, calcd:
3996 Da), peak b: unreacted Rev1, peak d: ligation product (Rev2–Rev1,
obs. : 9260.0 Da, calcd 9259.1 Da). Inset : deconvoluted ESI-MS. C) Ligation re-
action between Rev2–Rev1 and Rev3 (1.2 equiv) after 18 h. Peak e: hydro-
lyzed Rev3 (obs. : 4021 Da, calcd: 4021 Da), Peak f: Rev3 after thiol exchange
with benzyl mercaptan (obs. : 4127 Da, calcd: 4128 Da), peak g: ligation
product Rev3–Rev2–Rev1 (obs. : 13263.2 Da, calcd 13262.5 Da). Inset : de-
convoluted ESI-MS. *: thiol additives. D) Acm deprotection reaction of Rev3–
Rev2–Rev1. Peak h: HIV-1 Rev(1–116) (obs. : 13056.9 Da (insets), calcd:
13056.7 Da).
ChemBioChem 0000, 00, 1 – 9  2011 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim www.chembiochem.org &3&
These are not the final page numbers! 
Synthesis and Expression of HIV-1 Rev
the possibility of disulfide-bond formation, and thus maintains
a free N-terminal Cys; and thirdly, it serves as the hydrogen
donor[34,47] (instead of tert-butylmercaptan) in the desulfuriza-
tion reaction. After examining several thiol additives, including
benzyl mercaptan, thiophenol, MPAA, and MESNa, in the desul-
furization reaction on a model peptide (CLYRAG), we found
that the MESNa gave the best results and allowed rapid and
efficient desulfurization (Supporting Information). All other
thiols, although affording ligation at a faster rate, failed to
allow one-pot desulfurization in model ligations with CLYRAG
and Thz-LYRAG-thioester (Supporting Information). Based on
these results, we then carried out all the synthesis steps up to
the Acm removal (Scheme 1) as a one-pot synthesis, followed
by a purification and final deprotection to give the Rev protein
in 15% overall isolated yield (Supporting Information). These
results testify to the advantages of carrying out sequential liga-
tion and desulfurization in a one-pot manner, to increase the
yield of the target protein.[46,52]
Expression of HIV-1 Rev
In parallel to our synthesis strategy, we developed a new pro-
tocol for the expression and purification of recombinant Rev to
increase solubility, facilitate the purification and obtain higher
expression yield. We used a modified pET22 vector (pET-HLT)
that contained a His6-tag for IMAC purification, a Lipoyl
domain for increasing solubility and expression, and a TEV pro-
tease cleavage site. The gene for Rev (HXB2 isolate) was ampli-
fied from pCsRevsg143 by PCR, and subcloned into pET-HLT.
The protein was expressed in BL21-CodonPlus-RIL, and then
purified by using three sequential chromatographic purifica-
tion procedures: affinity purification on a Ni-Sepharose col-
umn, followed by cleavage by TEV protease; purification on a
cation-exchange column; and final purification on a gel filtra-
tion column (Experimental Section). This procedure afforded a
folded (Figure 2), highly pure, and homogeneous protein
(single peak on the Superdex 75 gel filtration column, Fig-
ure 3C). SDS-PAGE and Western blot analysis showed a single
band with an apparent Mw of 20 kDa (Figure 3D). By using
this procedure, we were able to achieve a final yield of 32 mg
of pure native Rev from 1 L culture, superior to that in a previ-
ous report (9 mgL1).[53]
Conclusions
In summary, we present two novel and efficient methods of
preparing the HIV-1 Rev protein in high quantity and purity. In
the synthesis approach, we applied different methods to syn-
thesize the thioester fragments, and revealed their advantages
and disadvantages. An important aspect of our synthesis is the
use of the one-pot approach to include the desulfurization
step; this reduces the number of purification steps and signifi-
cantly increases the synthesis yield. Having these synthesis
tools in hand, we plan to study the effect of post-translational
modifications[54–56] on the function and structure of the Rev
protein, along with introducing chemical switches[57,58] to con-
trol Rev folding and self-assembly, to better understand these
processes on the function of Rev protein.[4,53,59]
Figure 2. CD spectra of A) recombinant and B) synthesized Rev. Both spectra show typical minima at 208 and 222 nm, consistent with a predominantly helical
structure.
Scheme 2. Formylation of Rev2-Nbz by the Vilsmeier–Haack reaction during
the activation step by using p-nitrophenylchloroformate in DMF. a) Fmoc-
Dbz, HBTU/HOBt/DIEA, DMF; b) 20% piperidine; c) Fmoc SPPS; d) p-nitrophe-
nylchloroformate; e) 0.5m DIEA, DMF; f) cleavage (TFA,TIS, H2O); g) R-SH.
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Using our recombinant expression and purification ap-
proaches, we were able to achieve a yield of 32 mg pure pro-
tein per liter of medium, compared to the 9 mg per liter previ-
ously reported.[53] The purified protein is stable (it does not ag-
gregate) at concentrations up to 200 mm in the absence of sta-
bilizing additives. Higher concentrations were reached when
crystallization of the protein in complex was studied;[9] howev-
er, our purification protocol is the first for obtaining high con-
centrations of free native soluble Rev in solution with no addi-
tives. The recombinant protein was also essential in the devel-
opment of our optimal chemical synthesis of Rev, and enabled
us to improve the synthesis and to develop a method for
transferring the chemically synthesized protein to a buffer suit-
able for biological experiments. Both new methods serve as a
basis for further research into Rev, and will lead to a better un-
derstating of virus activity and regulation.
Experimental Section
Material and methods
SPPS: Peptide synthesis was carried out in syringes equipped with
teflon filters (Torviq, Niles, MI), or by using a CS336X peptide syn-
thesizer (CS Bio Co, Menlo Park, CA). Except where described differ-
ently, all reactions were carried out at room temperature. Resins,
protected amino acids, and HBTU were purchased from Novabio-
chem. DMF was purchased in biotech grade.
Peptide analysis: Analytical HPLC, for monitoring progress of reac-
tions and peptide purity, was performed on a SpectraSYSTEM
P4000 (Thermo Scientific) with a Jupiter C5 (Phenonenex, Torrance,
CA) analytical column (5mm, C18/C4, 300 , 1504.6 mm,
1.2 mLmin1). Preparative HPLC was performed on a Waters 2489/
2535 instrument with a preparative column (Jupiter 10 micron,
C18/C4, 300 , 25021.2 mm, 25 mLmin1). Mass spectrometry
analysis was carried out by using an LCQ Fleet Ion Trap (Thermo
Scientific).
Synthesis of Rev1: The synthesis was carried out by using Fmoc
SPPS on Rink amide resin (0.2 mmolg1, 0.1 mmol scale). The syn-
thesis was performed on a C5BIO peptide synthesizer in the pres-
ence of amino acid (AA, 4 equiv), DIEA (8 equiv) and HBTU/HOBt
(4 equiv) for the initial loading of the resin. The coupling was left
for 1 h, and Fmoc-deprotection was achieved by using 20% piperi-
dine with 5/10/5 min cycles.
Cleavage from the resin: A mixture of TFA, triisopropylsilane (TIS),
and water (95:2.5:2.5) was added to the dried peptide–resin, and
the reaction mixture was shaken for 2 h at RT. The resin was re-
moved by filtration, and was washed with TFA (22 mL). To precip-
itate the peptide, the combined filtrate was added drop-wise to a
tenfold volume of cold ether, followed by centrifugation, decanting
of ether, and desolvation of residues in acetonitrile/water for the
HPLC purification step.
Synthesis of Rev2 thioester: The synthesis was started by swelling
trichloroacetimidate Wang resin (133 mg, 0.1 mmol) with DCM for
30 min. The resin was washed with dry THF several times, followed
by the addition of Fmoc-Ser-OAll (110 mg, 0.30 mmol) dissolved in
dry THF (2 mL). After 2 min, boron trifluoride diethyl etherate (6 mL,
0.05 mmol) was added, stirred briefly, and left for 1 h. Subsequent-
ly, methanol (0.2 mL) was added for capping the unreacted sites,
and the reaction was allowed to proceed for a further 5 min, then
washed several times with THF and DMF. SPPS for the remaining
amino acids was achieved by using a peptide synthesizer as de-
scribed above.
Allyl deprotection: the resin was swollen with DCM for 10 min, fol-
lowed by treatment with N-methylaniline (NMA; 110 mL, 1 mmol)
dissolved in dry DCM (0.5 mL), followed by the addition of Pd0
(25 mg, 0.02 mmol in 1.5 mL DCM) and left to shake for 30 min.
Subsequently, the resin was washed several times with DCM. The
above procedure was repeated twice, followed by a final DMF
wash.
Thioesterification: The resin was treated with methyl 3-mercapto-
propionate (20 equiv, 111 mL, 1 mmol, dissolved in 0.5 mL DMF),
ByBOP (3 equiv, 78 mg, 0.15 mmol) and DIEA (3 equiv, 26 mL,
0.15 mmol, dissolved in 0.5 mL DMF). The reaction was followed by
analytical cleavage from the resin (complete coupling was indicat-
ed after 12 h). Cleavage and purification were carried out as de-
scribed for Rev1.
Synthesis of Rev3 thioester by side-chain anchoring: The synthesis
was carried out by using Fmoc-Glu-OAll coupled to Rink amide
resin (0.6 mmolg1, 0.1 mmol scale). The peptide synthesis was
performed on a peptide synthesizer as described above. The cou-
pling was left for 1 h, and Fmoc-deprotection was achieved by
using 20% piperidine with 5/10/5 min cycles. The deallylation and
thioesterification steps were preformed as described for the syn-
thesis of the Rev2 thioester. Cleavage and purification were carried
out as described for Rev1.
Synthesis of Rev2-Nbz: The synthesis was carried out by using the
N-acylurea method (Scheme 2) on Rink amide resin (0.6 mmolg1,
Figure 3. Purification of recombinant Rev. UV absorbance chromatograms at
280 nm (c) and 260 nm (a) of HLT-Rev following serial purification by
A) Ni column, B) cation exchange, and C) gel filtration. D) SDS-PAGE of re-
combinant Rev showing purity of the protein preparation.
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0.1 mmol scale). Amino acids and HOBt/HBTU were used in four-
fold excess of the initial loading of the resin. DIEA was used in
eightfold excess. The first two amino acids were double coupled
for 1 h. Fmoc deprotection was achieved by treatment of the resin
with 20% piperidine (33 min). The remaining amino acids were
coupled by using a peptide synthesizer as described above.
On-resin activation: After completion of peptide synthesis, the resin
was washed with DMF, and a solution of p-nitrophenylchlorofor-
mate (100 mg, 5 equiv. in 10 mL DMF) was then added and shaken
for 1 h at RT. The resin was washed with DMF (35 mL). Following
these steps, a solution of DIEA (0.5m in 5 mL DMF) was added, and
the mixture was shaken for an additional 30 min. The resin was
washed with DMF (35 mL). Cleavage and purification were car-
ried out as described for Rev 1.
Synthesis of the peptide LeuLeu-Nbz: the synthesis and activation
were carried out as for Rev2-Nbz described above.
Rev assembly by NCL
Ligation of Rev1 and Rev2 : Rev1 (10.0 mg, 1.9 mmol) and Rev2
(8.8 mg, 2.08 mmol) were dissolved in Gn.HCl (950 mL, 6m) with
phosphate buffer (200 mm, pH 7.0). Benzylmercaptan (19 mL) and
thiophenol (19 mL) were added, and the solution was incubated at
37 8C. The progress of reaction was monitored by using an analyti-
cal C4 column with a gradient of 5–50% B over 40 min.
Thz to Cys conversion: Following ligation, the reaction mixture was
diluted to 1 mm in a solution of methoxylamine (0.4m, containing
30 equiv. TCEP, pH 4) and incubated at 37 8C. The progress of the
reaction was monitored by using an analytical C4 column with a
gradient of 5–50% B over 40 min. Purification and lyophilization
afforded the desired product in 35% yield (6.1 mg).
Ligation of Rev2–Rev1 to Rev3 : Rev2–Rev1 (6.1 mg, 0.65 mmol) and
Rev3 (3.0 mg, 0.72 mmol) were dissolved in Gn.HCl (280 mL, 6m)
with phosphate buffer (200 mm, pH 7.0). Benzylmercaptan (5.6 mL)
and thiophenol (5.6 mL) were added, and the solution was incubat-
ed at 37 8C. The progress of reaction was monitored by using an
analytical C4 column with a gradient of 5–50% B over 40 min.
Purification and lyophilization afforded the desired product in 35%
yield (3.0 mg).
Desulfurization of Rev3–Rev2–Rev1: The purified ligation product
was dissolved to a concentration of 2 mm in Gn.HCl (6m) with
phosphate buffer (200 mm, pH 7.4), and purged under argon. To
this solution, the same volume of TCEP (0.5m) was added, fol-
lowed by the addition of tert-butyl mercaptan (4%, v/v) and of the
radical initiator VA-044 (0.1m, 8%, v/v in Gn·HCl), and incubated at
37 8C for 12 h. The progress of reaction was monitored by using an
analytical C18 column with a gradient of 5–55% B over 30 min.
Purification and lyophilization afforded the desired product in 60%
yield (1.8 mg).
Acm deprotection: Desulfurized Rev3–Rev2–Rev1 was dissolved in
of 10% AcOH (160 mL, pH 4.0) containing 30 equiv. Hg(OAc)2. The
reaction mixture was mixed well and left at room temperature for
3 h. Following this, DTT (120 equiv) was added, and the mixture
was allowed to react for 24 h. The black precipitate was removed,
and the supernatant was collected for HPLC purification. The prog-
ress of reaction was monitored by using analytical C18 column
with a gradient of 5–55% B over 30 min. Purification and lyophili-
zation afforded the desired product in 60% yield (1 mg).
One-pot synthesis of Rev protein: Rev1 (5.0 mg, 0.95 mmol) and
Rev2 (4.4 mg, 1.04 mmol) were dissolved in of Gn.HCl (6m,150 mL)
with phosphate buffer (200 mm, pH 7.0). A solution of MESNa (5%,
w/v) was added, and the solution was incubated at 37 8C. After
completion of the ligation, the reaction mixture was diluted to
3 mm in methoxylamine solution (150 mL, 0.4m, pH 4, containing
30 equiv. TCEP) and incubated at 37 8C. Upon completion, the pH
of the reaction mixture was adjusted to approximately pH 7 with
NaOH (1m), followed by the addition of Rev3 (2.7 mg, 0.66 mmol).
The reaction was left at 37 8C for an additional 24 h. Upon comple-
tion of the second ligation, VA-044 (4 equiv.) was added. In all
these steps, the progress of different reaction steps were moni-
tored by using an analytical C4 column with a gradient of 5—50%
B over 30 min. Purification and lyophilization steps afforded the
desired product in 25% yield (3.3 mg).
Constructing the plasmid
The gene for the HXB2 isolate Rev was amplified from
pCsRevsg143 plasmid (kindly donated by Prof. Dr. Ruth Brack-
Werner, German Research Center for Environmental Health,
Munich, Germany) by using PCR with the following oligonucleo-
tides: GTATACCGgaattcGCAGGAAGAAGCGGAGACAGC (forward
primer, EcoRI restriction site underlined) and CTAGTTTAgcggccgc-
TTACTCTTTAGTTCCTGACTCGAGTACTGTAGG (reverse primer, Not1
site). Following digestion of the PCR product and pET-HLT with
NotI and EcoRI, the Rev gene was ligated into the pET-HLT plasmid
by using T4 DNA ligase (Takara, Shiga, Japan). The ligated vector
was transformed into DH5a bacterial strain, and the resulting colo-
nies were screened by PCR and verified by sequencing (Center for
Genomic technologies, Hebrew University). As a result of the sub-
cloning of the Rev into the pET-HLT, a linker of six residues
(GGSGIQ) remained between the TEV recognition site and the Rev
gene. Upon cleavage of the protein product by TEV protease, the
Rev protein included a GGSGIQ tail at the N terminus (Figure 4).
Production of Recombinant Rev: The pET-HLT-Rev construct was
transformed into BL21CodonPlus RIL (Stratagene). Cells were then
plated on ampicillin-selective plates, and incubated for 16 h. The
next day, colonies were transferred to 2YT medium (3 mL) con-
taining of ampicillin (33 mgL1), and the culture was grown for an
additional 16 h in an incubator-shaker at 37 8C. The 16 h growth
was then transferred (1:100) into an Erlenmeyer flask containing
2YT medium supplemented with antibiotics, and the culture was
grown at 37 8C until OD600 reached 0.7. The flask was transferred
into a 17C shaker, and induced with IPTG (0.4 mm). Cells were har-
vested 16 h post-induction. Cells were collected by centrifugation
and stored at 70 8C. The bacterial pellet was then lysed by using
a microfluidizer (M-110 EHIS; Microfluidics, Newton, MA) and the
samples were analyzed on SDS-PAGE and by Western blot, with
anti-Rev antibody.
Recombinant Rev purification: Cell pellets from 1.5 L cultures
were thawed on ice and suspended in buffer A (NaPi (25 mm,
pH 7.4), NaCl (500 mm), bMe (2 mm), and imidazole (10 mm)), sup-
Figure 4. Rev (HXB2 isolate) sequence with HLT-tag. Residues 1–111: HLT
fusion tag. Residues 100–107: TEV protease cleavage site. Residues 106–111:
additional residues resulting from cloning. Residues 112–226: sequence of
Rev.
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plemented with MgCl2 (10 mm), PMSF (1 mm), lysozyme
(0.2 mgmL1), and DNaseA (50 mgmL1). Cells were disrupted me-
chanically by using a microfluidizer. The soluble supernatant was
separated from the insoluble pellet by centrifugation (20000g,
20 min, 4 8C) and filtered. Chromatography was performed by
using the AKTA Explorer FPLC system (GE Healthcare Bio-Sciences
AB, Uppsala, Sweden). Supernatant was loaded on a Ni-Sepharose
FF column (GE Healthcare) pre-equilibrated with buffer A, and ex-
tensively washed. Protein was eluted from the affinity column by
gradually increased imidazole concentration (up to 250 mm). HLT-
Rev fractions were pooled according to their molecular weight on
SDS-PAGE separation, and incubated overnight with TEV protease
at a 1:20 molar ratio (TEV:HLT-Rev) at 4 8C). After incubation, the
cleaved protein was diluted (1:7) in buffer C (NaPi (25 mm, pH 7.4),
NaCl (50 mm), 10% glycerol, and bMe (2 mm)) in order to reduce
conductivity before loading on an 8 mL Resource 30S cation ex-
change column (GE Healthcare). Column was eluted with a compo-
site NaCl gradient, and the digested Rev eluted at ~0.5m NaCl in
buffer C. To further increase the purity of the protein, an additional
purification step was performed by using a 200 mL (951.6 cm)
gel filtration Superdex 75 column (GE Healthcare), pre-equilibrated
in the final storage buffer (NaPi (50 mm), NaCl (500 mm), 10% gly-
cerol, DTT (1 mm), and 0.02% NaN3. Rev-containing fractions were
pooled, quantified by spectroscopy absorbance at 280 nm, concen-
trated to 200 mm, aliquoted, and stored at 80 8C after fast freez-
ing.
CD: CD spectra were recorded by using a J-810 spectropolarimeter
(Jasco) in a 0.1 cm quartz cuvette. Far-UV CD spectra were collect-
ed over 190–260 nm at 4 8C. The synthetic protein was refolded by
using the following buffer: NaPi (50 mm), NaCl (500 mm), 10%
glycerol, DTT (1 mm) and 0.02% NaN3. Protein was obtained at
50 mm final concentration.
Western blot: After SDS-PAGE, samples were transferred onto a
cellulose nitrate membrane. The membrane was blocked for 1 h in
PBS containing 1% non-fat milk powder, 3% BSA, 18% Glucose,
10% glycerol and 0.5% Tween-20. The cellulose membrane was
then incubated in Ab buffer (PBS buffer containing 5% non-fat
dried milk, 0.05% Tween-20) with the primary antibody, rat anti-
Rev Ab (1:50, kindly donated by Dr. Brack-Werner, German Re-
search Center for Environmental Health, Munich, Germany). After
three washes with TBST (Tris·HCl (10 mm, pH 8.0), NaCl (150 mm),
and 0.01% Tween-20), the membrane was incubated once more
for 1 h in Ab buffer with the secondary antibody, HRP-conjugated
donkey anti-rat Ab (1:1000, Jackson ImmunoResearch Europe Ltd. ,
Suffolk, UK). The membrane was then washed again with TBST and
the protein bands were visualized by using chemical luminescence
with luminol.
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Chemical Synthesis and Expression of
the HIV-1 Rev Protein
Winning HIV-1 Rev: The protein HIV-1
Rev plays an important role in the HIV
lifecycle; however, its high tendency to
aggregate has hindered several studies
that aimed at deciphering better its
structure and function. Two highly re-
producible methods to generate this
protein in large quantities, based on
chemical synthesis and recombinant
expression, are presented.
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